Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) shares are -22.20% down in the year-to-date (YTD) period and have moved -4.23% or -$0.18 lower in the latest trading session. Comparatively, the stock is down -17.33% over the trailing 3-month period. If we look at the shorter duration, its week performance is -1.00% and 10.31% over the month.
On September 14, 2018, Needham recommended the PGNX stock is a Buy, while earlier, Credit Suisse had Initiated the stock as a Outperform on December 07, 2018. 1 analysts offering the recommendations for the stock have a consensus rating of 2.00 to suggest that the PGNX stock is a “Moderate Sell. 0 of the 1 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 1 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $3.96 and analysts tracking its performance over the next 12 months have a consensus estimate price target of $6.75. The forecasts give the Progenics Pharmaceuticals Inc. stock a price target range of $6.50 on the higher side while at least one analyst think the stock could plunge to a low of $6.50. The two limits represent an upside potential of 39.08% or 39.08%.
Analysts estimate the earnings to increase 35.00% in the current quarter to -$0.22, up from the -$0.22 reported in the same quarter a year ago. For the current year, earnings should grow to an average of -$0.96, up 5.30% from -$0.8 reported last year. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between -$0.24 and -$0.24. Wall Street estimates earnings per share to be at an average of -$0.65 for the next year.
Insider Transactions Summary
According to SEC data, total insider shares purchases at the company stands at 10 over the last 12 months, while SEC filings reveal that there have been 0 insider sales over the same period. Insiders have purchases 860,887 shares while those sold by company executives and officers stand at 0. The last 3 months have seen insiders trade a total of 0 and 0 in purchases and sales respectively.
LTE Partners, LLC, a See Explanation of Responses at the company, bought 21,480 shares worth $106096.0 at $4.94 per share on Sep 09. The See Explanation of Responses had earlier bought another 72,023 PGNX shares valued at $359733.0 on Sep 09. The shares were bought at $4.99 per share. LTE Partners, LLC (See Explanation of Responses) bought 43,520 shares at $4.62 per share on Sep 05 for a total of $201097.0 while Velan Capital, L.P., (See Explanation of Responses) bought 243,614 shares on Sep 04 for $1.1 million with each share fetching $4.51.
Blueprint Medicines Corporation (NASDAQ:BPMC), on the other hand, is trading around $58.63 with a market cap of $3.20B and analyst research firms have a negative stance on its shares. Analysts predict that the stock will reach $104.64 and spell out a more modest performance – a 43.97% return. Some analysts are even forecasting -$8.87 per share in earnings this year on a short term (1 year) basis.
Insiders have transacted a total of 55 times at Blueprint Medicines Corporation over the last 6 months, with insider purchases undertaken 23 times and accounting for 262,130 shares. Insider sales totaled 123,131 shares over the same period, with these deals completed in 32 transactions. Looking at these numbers, we realize that net purchases over that period are -9.0 shares. Insiders now hold a total of 772.59k shares after the latest sales, with 44.80% net shares purchased.
Insiders own 0.80% of the company shares, while shares held by institutions stand at 95.60% with a share float percentage of 52.64M. Investors are also buoyed by the number of investors in a company, with Blueprint Medicines Corporation having a total of 315 institutions that hold shares in the company. The top two institutional holders are FMR, LLC with over 7.38 million shares worth more than $591.15 million. As of Dec 30, 2019, FMR, LLC held 13.66% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the investment firm holding over 4.37 million shares as of Dec 30, 2019. The firm’s total holdings are worth over $349.92 million and represent 8.08% of shares outstanding.